EP1626981A4 - Dipeptidylpeptidase-geschützte proteine - Google Patents

Dipeptidylpeptidase-geschützte proteine

Info

Publication number
EP1626981A4
EP1626981A4 EP04717362A EP04717362A EP1626981A4 EP 1626981 A4 EP1626981 A4 EP 1626981A4 EP 04717362 A EP04717362 A EP 04717362A EP 04717362 A EP04717362 A EP 04717362A EP 1626981 A4 EP1626981 A4 EP 1626981A4
Authority
EP
European Patent Office
Prior art keywords
dipeptidyl
peptidase
protected proteins
proteins
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717362A
Other languages
English (en)
French (fr)
Other versions
EP1626981A2 (de
Inventor
Homayoun Sadeghi
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Technology Inc
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,094 external-priority patent/US7176278B2/en
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of EP1626981A2 publication Critical patent/EP1626981A2/de
Publication of EP1626981A4 publication Critical patent/EP1626981A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04717362A 2003-03-04 2004-03-04 Dipeptidylpeptidase-geschützte proteine Withdrawn EP1626981A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/378,094 US7176278B2 (en) 2001-08-30 2003-03-04 Modified transferrin fusion proteins
PCT/US2003/026818 WO2004020405A2 (en) 2002-08-30 2003-08-28 Modified transferrin fusion proteins
PCT/US2004/006462 WO2004078777A2 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins

Publications (2)

Publication Number Publication Date
EP1626981A2 EP1626981A2 (de) 2006-02-22
EP1626981A4 true EP1626981A4 (de) 2006-11-22

Family

ID=32965093

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717362A Withdrawn EP1626981A4 (de) 2003-03-04 2004-03-04 Dipeptidylpeptidase-geschützte proteine

Country Status (2)

Country Link
EP (1) EP1626981A4 (de)
WO (1) WO2004078777A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406490A (zh) * 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
AU2006280004A1 (en) 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
EP2570133B1 (de) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagonanaloga mit physiologischer Löslichkeit und Stabilität
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
CA2646598C (en) * 2006-03-21 2014-08-19 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2059818A2 (de) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarker für die vorform von typ 2 diabetes und verfahren zum nachweis der an- oder abwesenheit einer vorform von typ 2 diabetes
US8114632B2 (en) 2006-06-21 2012-02-14 Biocon Limited Method of producing biologically active polypeptide having insulinotropic activity
EP2046826B1 (de) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Exendin-fusionsproteine
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007331195A1 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
EP2214691B1 (de) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Verbindungen mit glucagon-antagonistischer und glp-1-agonistischer wirkung
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (de) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Coagonisten des glucagon/glp-1 rezeptors
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
JP5887265B2 (ja) 2009-06-16 2016-03-16 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Ｇｉｐ受容体活性グルカゴン化合物
EP2512503A4 (de) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Coagonisten des glucagon/glp-1 rezeptors
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
EP2585102B1 (de) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Auf amid basierende insulin-prodrugs
KR102099462B1 (ko) 2010-11-30 2020-04-10 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
HUE035776T2 (en) 2011-06-22 2018-05-28 Univ Indiana Res & Tech Corp Glucagon / GLP-1 receptor coagulants
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
EP3206710B1 (de) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Inkretininsulinkonjugate
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
SG11202009467YA (en) 2018-04-05 2020-10-29 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP0978565A1 (de) * 1998-01-30 2000-02-09 Suntory Limited Verfahren zur herstellung eines peptids mittels eines hilfspeptids
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
WO2003016349A1 (fr) * 2001-07-19 2003-02-27 Shanghai Hua-Yi Bio-Tech Lab Methode de production d'un peptide 1 de type glucagon (glp-1) 7-36 et d'un analogue de glp-1
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978565A1 (de) * 1998-01-30 2000-02-09 Suntory Limited Verfahren zur herstellung eines peptids mittels eines hilfspeptids
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
WO2003016349A1 (fr) * 2001-07-19 2003-02-27 Shanghai Hua-Yi Bio-Tech Lab Methode de production d'un peptide 1 de type glucagon (glp-1) 7-36 et d'un analogue de glp-1
EP1408050A1 (de) * 2001-07-19 2004-04-14 Shanghai Hua-Yi Bio-Tech Lab Verfahren zur herstellung von glucagon-like-peptide 1 (glp 1)7-36 und eines glp-1-analogons
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADELHORST K ET AL: "STRUCTURE-ACTIVITY STUDIES OF GLUCAGON-LIKE PEPTIDE-1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 269, no. 9, 4 March 1994 (1994-03-04), pages 6275 - 6278, XP002045291, ISSN: 0021-9258 *
KAWAI K ET AL: "THE BIOLOGICAL EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND ITS STRUCTURE-ACTIVITY RELATIONSHIP", BIOMEDICAL RESEARCH, vol. 9, no. SUPPL 3, 1988, pages 213 - 217, XP000574772 *
KIEFFER T J ET AL: "DEGRADATION OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND TRUNCATED GLUCAGON-LIKE PEPTIDE 1 IN VITRO AND IN VIVO BY DIPEPTIDYL PEPTIDASE IV", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 136, no. 8, 1 August 1995 (1995-08-01), pages 3585 - 3596, XP000574863, ISSN: 0013-7227 *
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664 - 1669, XP002201014, ISSN: 0022-2623 *
OHNEDA A ET AL: "THE STRUCTURE-FUNCTION RELATIONSHIP OF GLP-1 RELATED PEPTIDES IN THE ENDOCRINE FUNCTION OF THE CANINE PANCREAS", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, TOHOKU UNIVERSITY MEDICAL PRESS, SENDAI, JP, vol. 165, no. 3, November 1991 (1991-11-01), pages 209 - 221, XP008014886, ISSN: 0040-8727 *
SVETLANA MOJSOV: "STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY OF GLUCAGON-LIKE PEPTIDE-I", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 40, no. 3 / 4, 1 September 1992 (1992-09-01), pages 333 - 343, XP000311244, ISSN: 0367-8377 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406490A (zh) * 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物

Also Published As

Publication number Publication date
WO2004078777A2 (en) 2004-09-16
EP1626981A2 (de) 2006-02-22
WO2004078777A3 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
EP1626981A4 (de) Dipeptidylpeptidase-geschützte proteine
EP1633834A4 (de) Verbessertes schmiermittel mit lebensmittelqualität
PL1714084T3 (pl) Piekarnik
GB0324265D0 (en) Peptide
EP1614695A4 (de) Polypeptid
GB0311108D0 (en) Proteins
GB0306980D0 (en) Proteins
GB0305576D0 (en) Proteins
GB0300506D0 (en) Proteins
GB0304656D0 (en) Proteins
GB0304921D0 (en) Proteins
GB0300503D0 (en) Proteins
GB0330036D0 (en) Proteins
GB0304661D0 (en) Proteins
GB0318686D0 (en) Proteins
GB0319586D0 (en) Proteins
GB0326291D0 (en) Proteins
GB0326636D0 (en) Proteins
GB0329145D0 (en) Proteins
GB0329664D0 (en) Proteins
GB0328496D0 (en) Child-net protect
GB0327685D0 (en) Polypeptide
GB0308088D0 (en) Polypeptide
GB0303133D0 (en) Polypeptide
GB0303186D0 (en) Polypeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061025

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS TECHNOLOGY, INC.

17Q First examination report despatched

Effective date: 20071008

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090207